MANGILI, FEDERICA
MANGILI, FEDERICA
Dipartimento di Scienze Cliniche e di Comunità
AZD1775: effect of monotherapy or EDP-M combination in the treatment of ACC preclinical models
2025 E. Nozza, R. Catalano, G. Di Muro, S. Di Bari, G. Lopez, G. Marra, E. Esposito, F. Mangili, D. Treppiedi, M. Battistin, G. Mantovani, E. Peverelli
Potential antitumoral effects of SRPK1 inhibition through modulation of VEGF splicing in pituitary somatotroph tumoral cells
2025 D. Treppiedi, S. Di Bari, F. Mangili, A.M. Barbieri, G. Di Muro, M. Locatelli, A. Mangone, E. Peverelli, G. Mantovani
Potential antitumoral effects through modulation of VEGF-A splicing in rat somatotroph and lactotroph pituitary tumoral cells
2024 D. Treppiedi, S. Di Bari, F. Mangili, G. Marra, A.M. Barbieri, F. Arlati, M. Locatelli, A. Lania, E. Peverelli, G. Mantovani
The novel SST3 agonist ITF2984 exerts antimitotic and proapoptotic effects in human non-functioning pituitary neuroendocrine tumor (NF-PitNET) cells
2024 G. Di Muro, R. Catalano, D. Treppiedi, A.M. Barbieri, F. Mangili, G. Marra, S. Di Bari, E. Esposito, E. Nozza, A. Lania, M. Locatelli, D. Modena, C. Steinkuhler, E. Peverelli, G. Mantovani
MOLECULAR MECHANISMS UNDERLYING CLINICAL BEHAVIOR OF NEUROENDOCRINE TUMORS: STUDY OF NEW POSSIBLE BIOMARKERS PREDICTABLE OF PHARMACOLOGICAL RESISTANCE AND TARGETS
2023 F. Mangili
A β-Arrestin 2-Biased Dopamine Receptor Type 2 (DRD2) Agonist Is More Efficacious Than Cabergoline in Reducing Cell Proliferation in PRL-Secreting but Not in Non-Functioning Pituitary Tumor Cells
2023 G. Di Muro, F. Mangili, E. Esposito, A.M. Barbieri, R. Catalano, D. Treppiedi, G. Marra, E. Nozza, A.G.A. Lania, E. Ferrante, M. Locatelli, M. Arosio, E. Peverelli, G. Mantovani
IGF2R: a new player in the insulin-like growth factor 2 (IGF2) pathway sustaining adrenocortical carcinoma cells growth
2023 E. Nozza, R. Catalano, E. Esposito, A.M. Barbieri, G. Marra, D. Treppiedi, G. Di Muro, F. Mangili, H. Constanze, S. Sigala, S. Palmieri, S. Frigerio, E. Ferrante, M. Arosio, G. Mantovani, E. Peverelli
DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells
2022 F. Mangili, E. Esposito, D. Treppiedi, R. Catalano, G. Marra, G. Di Muro, A.M. Barbieri, M. Locatelli, A.G. Lania, A. Mangone, A. Spada, M. Arosio, E. Peverelli, G. Mantovani
Role of filamin A in the pathogenesis of neuroendocrine tumors and adrenal cancer
2022 D. Treppiedi, R. Catalano, F. Mangili, G. Mantovani, E. Peverelli
P720R USP8 Mutation Is Associated with a Better Responsiveness to Pasireotide in ACTH-Secreting PitNETs
2022 D. Treppiedi, G. Marra, G. DI MURO, E. Esposito, A.M. Barbieri, R. Catalano, F. Mangili, F. Bravi, M. Locatelli, A. Gerardo Lania, E. Ferrante, R. Indirli, E. Nozza, F. Arlati, A. Spada, M. Arosio, G. Mantovani, E.M. Peverelli
Pituitary tumors: genetic and molecular factors underlying pathogenesis and clinical behavior
2022 A. Spada, G. Mantovani, A. Lania, D. Treppiedi, F. Mangili, R. Catalano, G. Carosi, E. Sala, E. Peverelli
SF3B1: hotspot mutazionale nei prolattinomi
2021 G. Mantovani, F. Mangili
Drug resistance in pituitary tumours: from cell membrane to intracellular signalling
2021 E. Peverelli, D. Treppiedi, F. Mangili, R. Catalano, A. Spada, G. Mantovani
β-arrestin 2 is required for dopamine receptor type 2 inhibitory effects on AKT phosphorylation and cell proliferation in pituitary tumors
2021 F. Mangili, E. Giardino, D. Treppiedi, A.M. Barbieri, R. Catalano, M. Locatelli, A.G. Lania, A. Spada, M. Arosio, G. Mantovani, E. Peverelli
Genetic profiling of a cohort of Italian patients with ACTH-secreting pituitary tumors and characterization of a novel USP8 gene variant
2021 D. Treppiedi, A.M. Barbieri, G. Di Muro, G. Marra, F. Mangili, R. Catalano, E. Esposito, E. Ferrante, A.L. Serban, M. Locatelli, A.G. Lania, A. Spada, M. Arosio, E. Peverelli, G. Mantovani
The cytoskeleton actin binding protein filamin A impairs both IGF2 mitogenic effects and the efficacy of IGF1R inhibitors in adrenocortical cancer cells
2021 R. Catalano, E. Giardino, D. Treppiedi, F. Mangili, V. Morelli, F.M. Elli, A.L. Serban, M. Luconi, M. Mannelli, A. Spada, M. Arosio, G. Mantovani, E. Peverelli
A novel mechanism regulating dopamine receptor type 2 (DRD2) signal transduction in pituitary tumoral cells: the role of cAMP/PKA-induced filamin A (FLNA) phosphorylation
2021 F. Mangili, D. Treppiedi, R. Catalano, G. Marra, G. DI MURO, A. Spada, M. Arosio, E.M. Peverelli, G. Mantovani
Un agonista del recettore della Somatostatina di tipo 3 (SSTR3) mostra effetti antitumorali in modelli sperimentali di tumori ipofisari non funzionanti
2020 G. Mantovani, F. Mangili
Cytoskeleton protein Filamin A is required for efficient Somatostatin receptor type 2 internalization and recycling through Rab5 and Rab4 sorting endosomes in tumor somatotroph cells
2020 D. Treppiedi, F. Mangili, E. Giardino, R. Catalano, M. Locatelli, A. Lania, A. Spada, M. Arosio, D. Calebiro, G. Mantovani, E. Peverelli
Octreotide and pasireotide effects on medullary thyroid carcinoma (MTC) cells growth, migration and invasion
2020 E. Giardino, R. Catalano, F. Mangili, A.M. Barbieri, D. Treppiedi, F.M. Elli, A. Dolci, A. Contarino, A. Spada, M. Arosio, G. Mantovani, E. Peverelli